Cargando…
Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials
OBJECTIVE—Despite experimental data suggesting a protective effect of peroxisome proliferator–activated receptor-γ agonists with respect to malignancies, results of available epidemiological studies on the incidence of cancer in rosiglitazone-treated patients are not univocal. The aim of this meta-a...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453648/ https://www.ncbi.nlm.nih.gov/pubmed/18375416 http://dx.doi.org/10.2337/dc07-2308 |